The company develops T cell engager antibodies that selectively deplete pathogenic immune cells, aiming to induce long-term remission in patients with chronic immune-mediated diseases. This therapeutic platform seeks to eliminate the need for continuous immunosuppression by resetting the immune system.
Funding
$120M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
NVTFounders
Product
Problem
Current treatments for chronic immune-mediated diseases, particularly B cell mediated diseases, often require continuous immunosuppressive therapy, which can be minimally effective and highly toxic. These treatments fail to address the underlying cause of the disease, leading to a need for more targeted and durable therapeutic approaches.
Solution
Ouro Medicines is developing immune reset therapeutics using T cell engager antibodies (TCEs) to selectively deplete pathogenic immune cells and induce long-term remission in patients with chronic immune-mediated diseases. Their approach aims to reset the immune system by precisely targeting and depleting specific pathogenic cell populations, potentially eliminating the need for ongoing immunosuppression. Ouro's lead product candidate, OM336, is a BCMA-directed, bispecific T cell engager with ongoing Phase 2 studies in multiple myeloma, and planned Phase 1 studies in B cell mediated diseases such as systemic lupus erythematosus, scleroderma, rheumatoid arthritis, and Sjögren’s. The company is also advancing discovery programs targeting additional dimensions of B cell biology and applying protein engineering expertise to develop next-generation TCEs.
Target Audience
The primary target audience includes patients suffering from chronic immune-mediated diseases, particularly B cell mediated diseases such as systemic lupus erythematosus, scleroderma, rheumatoid arthritis, and Sjögren’s, as well as the physicians who treat them.
Features
- Utilizes T cell engager antibodies (TCEs) for targeted depletion of pathogenic immune cells.
- Lead candidate OM336 is a BCMA-directed, bispecific T cell engager.
- OM336 has demonstrated high specificity and potency for near-complete B cell depletion.
- Focus on achieving immunological "reset" and durable remissions without continuous immunosuppression.
- Discovery programs targeting additional dimensions of B cell biology.
- Protein engineering expertise applied to next-generation versions of novel TCEs.